Two things, done properly: a place to track what actually matters while you're on incretin therapy, and a price comparison that compares like with like.
Built by someone taking these medicines, who also happens to read the trial data for a living.
First
Not a mood diary with a weight box. One timeline, with the reference ranges and risk thresholds a clinician would actually use.
Alongside
Most comparisons list a headline price per pen and stop. That is not a comparison — it is a coincidence. We normalise before we rank.
Because the existing apps are built for engagement, and the existing price sites go out of date quietly. Neither failure is malicious. They just aren't built by anyone who has to defend a number.
incretly is being built by an NHS hospital consultant — a doctor who has spent a career reading scans, reference ranges and trial estimands, and who is on GLP-1 therapy personally. That combination is the whole point: the features come from using the thing, and the rigour comes from the day job.
So: no transformation photography, no "incredible results", no invented scores. Where a number has a confidence interval, you will see the confidence interval. Where a figure is a week old, it will say so. Where the evidence is thin, it will say that too.
incretly is an information and record-keeping project. No medicines are sold, supplied, promoted or advertised on this site, and nothing here is medical advice or a recommendation to start, stop or change any treatment. Decisions about prescription medicines belong with you and your own prescriber.